Bridgeway Capital Management LLC Makes New Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Bridgeway Capital Management LLC acquired a new position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 175,000 shares of the company’s stock, valued at approximately $530,000. Bridgeway Capital Management LLC owned approximately 0.25% of Zentalis Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ZNTL. Almitas Capital LLC increased its holdings in Zentalis Pharmaceuticals by 69.3% during the 4th quarter. Almitas Capital LLC now owns 1,626,896 shares of the company’s stock valued at $4,929,000 after purchasing an additional 665,968 shares in the last quarter. Primecap Management Co. CA grew its holdings in shares of Zentalis Pharmaceuticals by 1.5% during the fourth quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company’s stock worth $4,608,000 after purchasing an additional 22,600 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company’s stock worth $3,979,000 after purchasing an additional 20,864 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Zentalis Pharmaceuticals by 75.7% in the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company’s stock valued at $2,605,000 after buying an additional 370,511 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Zentalis Pharmaceuticals by 22.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock valued at $1,507,000 after buying an additional 91,152 shares in the last quarter.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th. UBS Group dropped their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Wells Fargo & Company decreased their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday, March 27th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $8.24.

Insider Activity

In related news, Director Scott Dunseth Myers acquired 21,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 30th. The stock was acquired at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the acquisition, the director now owns 281,192 shares of the company’s stock, valued at $393,668.80. This trade represents a 8.07% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.60% of the stock is currently owned by company insiders.

Zentalis Pharmaceuticals Trading Down 2.4%

Shares of NASDAQ ZNTL opened at $1.23 on Monday. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.01 and a 1 year high of $13.24. The firm’s 50-day moving average is $1.50 and its 200-day moving average is $2.38. The firm has a market capitalization of $88.50 million, a PE ratio of -0.49 and a beta of 1.81.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.09. The business had revenue of $26.90 million during the quarter. As a group, equities research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.